Ridgeback Biotherapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3480 Main Hwy, Miami, Florida, 33133, Un...Phone Number
(786) 687-2495Website
www.ridgebackbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Ridgeback Biotherapeutics
Ridgeback Biotherapeutics develops potential medications for treating infectious diseases with limited or no treatment options, such as Ebola and COVID-19. They focus on illnesses that are poorly understood, committing resources and expertise early in the pharmaceutical development process. The company aims to provide innovative life-changing solutions for the health and safety of the global population. Their work addresses the needs of tens of millions suffering from known and emerging infectious diseases worldwide.Explore more
Ridgeback Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ridgeback Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ridgeback Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ridgeback Biotherapeutics recently announced quarterly report
Product Launch: Get notified when Ridgeback Biotherapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Ridgeback Biotherapeutics
Check out if Ridgeback Biotherapeutics is spiking on competitors!
Click to see if Ridgeback Biotherapeutics had a recent Job posting/layoffs
Check if Ridgeback Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Ridgeback Biotherapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Ridgeback Biotherapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Ridgeback Biotherapeutics
Compare insights from companies similar to Ridgeback Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ridgeback Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ridgeback Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ridgeback Biotherapeutics.
Ridgeback Biotherapeutics Tech Stack
A closer look at the technologies used by Ridgeback Biotherapeutics
Most Recent Scoops
Pain Point
Pain Point, Research & Development, Product Management, Safety
Project
Product Management, Compliance, Legal Affairs, Safety
Project
Research & Development, Product Management, Safety
Project
Ridgeback Biotherapeutics News & Media
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk AdultsMerck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (molnupiravir)Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)Merck Takes 3 Major Shots at COVID-19: Themis, IAVI and Ridgeback Bio
Merck has largely stayed out of the COVID-19 battle, but exploded into it with three major deals and collaborations today.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ridgeback Biotherapeutics
Sign Up For FreeTo access detailed company insights
Ridgeback Biotherapeutics develops potential medications for treating infectious diseases with limited or no treatment options, such as Ebola and COVID-19. They focus on illnesses that are poorly understood, committing resources and expertise early in the pharmaceutical development process. The company aims to provide innovative life-changing solut... Read More
